Advancements in Osteoarthritis Treatment

Calcium Channel Blockers: Demonstrating Long-Lasting Pain Relief and Cartilage Preservation in Patients with Moderate to Severe Osteoarthritis.

OVERVIEW:

Calosyn Pharma's lead candidate, CAL-05CR, builds on promising results in clinical trials as a novel treatment for osteoarthritis. Through rigorous clinical studies, Calosyn demonstrated the ability to reduce pain and preserve cartilage, making it a breakthrough in osteoarthritis therapy.

Pipeline:

Calosyn leverages the proven safety of Verapamil, using a known pathway and polymer to advance our therapeutic through Phase 2. With human data showing Verapamil’s effectiveness in reducing osteoarthitis pain, and a large market with few competitors, we are well-positioned to capture significant market share. Additionally, multiple strategic exits have been identified post-Phase 2.

Microsphere Innovation:

Further innovation in the formulation process led to a drastic improvement in cartilage preservation compared to earlier versions. The enhanced microsphere formulation offers sustained release, extending the therapeutic benefits of CAL-05CR and setting a new standard in osteoarthritis treatment.